Price Action Don’t Lie: Lion Biotechnologies Inc Can’t Burn Your Short Portfolio. Has Another Weak Session

Price Action Don't Lie: Lion Biotechnologies Inc Can't Burn Your Short Portfolio. Has Another Weak Session

The stock of Lion Biotechnologies Inc (NASDAQ:LBIO) is a huge mover today! About 192,028 shares traded hands. Lion Biotechnologies Inc (NASDAQ:LBIO) has risen 35.77% since March 9, 2016 and is uptrending. It has outperformed by 28.35% the S&P500.
The move comes after 7 months negative chart setup for the $383.44M company. It was reported on Oct, 12 by Barchart.com. We have $6.11 PT which if reached, will make NASDAQ:LBIO worth $42.18M less.

Analysts await Lion Biotechnologies Inc (NASDAQ:LBIO) to report earnings on November, 3. They expect $-0.21 EPS, down 31.25% or $0.05 from last year’s $-0.16 per share. After $-0.23 actual EPS reported by Lion Biotechnologies Inc for the previous quarter, Wall Street now forecasts -8.70% EPS growth.

According to Zacks Investment Research, “Lion Biotechnologies, Inc. is developing autologous cell therapies for the treatment of cancer. The Company’s lead product candidate, C?ntego(TM), is an autologous cell therapy indicated for the treatment of metastatic melanoma. Lion Biotechnologies, Inc., formerly known as Genesis Biopharma, Inc., is based in Woodland Hills, California.”

Insitutional Activity: The institutional sentiment increased to 1.67 in Q2 2016. Its up 0.34, from 1.33 in 2016Q1. The ratio improved, as 9 funds sold all Lion Biotechnologies Inc shares owned while 18 reduced positions. 9 funds bought stakes while 36 increased positions. They now own 42.74 million shares or 16.40% more from 36.71 million shares in 2016Q1.
Blackrock Fund Advsrs owns 1.81 million shares or 0% of their US portfolio. Vident Advisory Ltd Liability Com last reported 0.1% of its portfolio in the stock. New York State Common Retirement Fund, a New York-based fund reported 41,200 shares. Ubs Asset Mngmt Americas holds 0% of its portfolio in Lion Biotechnologies Inc (NASDAQ:LBIO) for 27,261 shares. Financial Bank Of America Corp De has 4,423 shares for 0% of their US portfolio. The Maryland-based Proshare Advisors Ltd Llc has invested 0% in Lion Biotechnologies Inc (NASDAQ:LBIO). Rhumbline Advisers holds 0% of its portfolio in Lion Biotechnologies Inc (NASDAQ:LBIO) for 52,276 shares. Creative Planning last reported 0% of its portfolio in the stock. Blackrock Grp holds 0% or 13,172 shares in its portfolio. Venbio Select Advisor Limited Liability Company holds 7.81% of its portfolio in Lion Biotechnologies Inc (NASDAQ:LBIO) for 4.34M shares. Moreover, Landscape Capital Management has 0.14% invested in Lion Biotechnologies Inc (NASDAQ:LBIO) for 130,196 shares. Peak6 Invests L P holds 0% or 13,468 shares in its portfolio. Gru One Trading L P last reported 0% of its portfolio in the stock. Metropolitan Life Commerce Ny, a New York-based fund reported 36,097 shares. Tower Ltd Company (Trc) last reported 0% of its portfolio in the stock.

Insider Transactions: Since August 22, 2016, the stock had 0 insider purchases, and 1 sale for $491,740 net activity. Hillsberg Sanford sold $491,740 worth of stock or 54,000 shares.

More notable recent Lion Biotechnologies Inc (NASDAQ:LBIO) news were published by: Fool.com which released: “Why Lion Biotechnologies Inc. Stock Is Roaring Higher Today” on June 03, 2016, also Thestreet.com with their article: “Lion Biotechnologies: Is This Tiny Biotech Company Ready to Roar?” published on June 06, 2016, Marketwatch.com published: “/quotes/zigman/3870025/realtime” on November 20, 2013. More interesting news about Lion Biotechnologies Inc (NASDAQ:LBIO) were released by: Quotes.Wsj.com and their article: “News Lion Biotechnologies Inc.LBIO” published on August 14, 2014 as well as Prnewswire.com‘s news article titled: “SHAREHOLDER ALERT: Purcell Julie & Lefkowitz LLP Is Investigating Lion …” with publication date: May 23, 2016.

LBIO Company Profile

Lion Biotechnologies, Inc., incorporated on September 17, 2007, is a clinical-stage biotechnology company. The Firm is focused on developing and commercializing cancer immunotherapy products designed to harness the power of a patient’s own immune system to eradicate cancer cells. The Company’s lead program is an adoptive cell therapy utilizing tumor-infiltrating lymphocytes (TIL), which are T cells derived from patients’ tumors, for the treatment of metastatic melanoma.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Leave a Comment